Context: Loss-of-function mutations in the POMC gene are associated with a syndrome with the characteristics of adrenal insufficiency, obesity, and red hair. We describe here a case of proopiomelanocortin (POMC) deficiency in which adrenal insufficiency was not treated until the fourth year of life. One of the disease-causative POMC mutations was characterized in vitro using a unique approach.
T he 7.8-kb human POMC gene, located on chromosome 2p23.3, encodes an evolutionarily conserved preprohormone, pro-opiomelanocortin (POMC), posttranslational processing of which gives rise to several tissue-specific repertoires of peptides with corticotrophic, opioid, and melanotrophic properties.
The biological significance of POMC-derived hormones is delineated by a syndrome that manifests with adrenal insufficiency, obesity, and red hair (1) ; this syndrome is a rare recessive disorder that is caused by loss-of-function mutations in the POMC gene. Its 3 major clinical components are attributed to deficiencies in adrenocorticotropic hormone (ACTH) in the anterior pituitary and melanocyte-stimulating hormone (MSH) peptides in hypothalamic nuclei and skin, respectively.
In the majority of patients described so far, POMC deficiency was recognized in the first months of life, which allowed early initiation of glucocorticoid therapy (2) . We present here a case of POMC deficiency in which adrenal insufficiency was neither diagnosed nor treated until the fourth year of life. DNA sequencing in the patient showed compound heterozygosity for p.W84X/ c.-11C.A mutations in the POMC gene. The p.W84X mutation (rs781244602) is predicted to result in total POMC deficiency. The c.-11C.A mutation has been described before (1) and is believed to completely abolish translation (3) . Using a messenger RNA (mRNA) transfection followed by an in vitro translation assay, we were able to directly demonstrate that the c.-11C.A mutation is compatible with translation of the main open reading frame (ORF) and, as a result, residual production of POMC preprohormone.
Case Report
A white boy from a nonconsanguineous family was born on his due date after an uneventful pregnancy, with a birth weight of 3.13 kg and length of 50 cm. The boy initially presented with prolonged neonatal jaundice. His developmental milestones were delayed by 2 to 3 months. By the end of his first year, growth acceleration was evident [ Fig. 1(A) ]. There were 2 episodes of hypoglycemia (glucose level, 1.7 mmol/L) at the ages of 1.5 and 3 years. In addition, there were recurrent self-resolving episodes of cholestasis, with bilirubin levels of up to 101 mmol/L. At 3.6 years, the boy's height was 118.5 cm [standard deviation (SD), 4.1 cm], and his weight was 28.5 kg [body mass index (BMI), 3.0 SD]. He had red hair and light skin. Plasma ACTH and serum cortisol were undetectable. He had elevated thyroid stimulating hormone of 8.0 mU/L (reference range, 0.6 to 5.8 mU/L) and free thyroxine of 7.6 pmol/L (reference range, 11.5 to 20.4 pmol/L), whereas serum bilirubin, alanine aminotransferase, and aspartate aminotransferase levels were within the reference ranges. Hydrocortisone replacement (10 mg/d) was initiated.
At 4.7 years, his height was 121.5 cm (SD, 3.2 cm), and his weight was 35.8 kg (BMI, 4.2 SD) [ Fig. 1(B) ]. His thyroid stimulating hormone level was 6.4 mU/L (reference range, 0.7 to 6.0 mU/L), and his free thyroxine level was 15.9 pmol/L (reference range, 12.3 to 22.8 pmol/L). POMC deficiency was suspected. A written informed consent for genetic studies was obtained from the patient's parents, and the protocol was approved by the local institutional review board.
Sanger sequencing of the POMC gene revealed 2 heterozygous mutations: cytosine to adenine transversion at position -11 (c.-11C.A) [ Fig. 1(C) ], and c.251G.A transition resulting in p.W84X substitution [ Fig. 1(D) ]. The c.-11C.A mutation was inherited from the mother, and the p.W84X substitution was inherited from the father. The p.W84X variant is listed in the Exome Aggregation Consortium database with allele frequency 0.00017 (4). The mutation is located in the moiety of the N-terminal peptide and is predicted to result in complete deficiency of ACTHs and MSHs. The c.-11C.A mutation has been reported before (1) and was shown to affect translation (3). To quantitate the effect of c.-11C.A on translation, we prepared reporter constructs encoding firefly luciferase [ Fig. 2(A) ] and analyzed their translation efficiency both in cultured human cells and in a cell-free in vitro system (Supplemental material). To exclude a possible impact of transcription and other DNA-related events, we used an mRNA transfection technique for the living cells (5) .
As expected, the upstream AUG (uAUG) codon inhibited translation of the main ORF [ Fig. 2(B) ]. The mutation led to fivefold to sixfold reduction in the luciferase level in transfected cells; however, the residual translation of mutation-wild-type reporter persisted [ Fig.  2(B) ]. Similar results were obtained in the cell-free translation system; in this case, the effect of the mutation was even lower [ Fig. 2(C) ].
Discussion
The boy described in the current report presented in the first months of life with recurrent episodes of cholestasis and growth acceleration, well-known features of isolated glucocorticoid deficiency, which together with red hair could have led to an earlier diagnosis of POMC deficiency. It should be pointed out, however, that the degree of obesity in the first 2 years was quite moderate, with the BMI near the upper normal limit for age [ Fig. 1(B) ]. This together with the late presentation of hypoglycemia may, at least in part, explain the delay in diagnosis and initiation of treatment. It is noteworthy that hydrocortisone at a "physiological" dose of 10 mg/m 2 resulted in a dramatic progression in obesity, with a BMI increase from 3.0 to 4.2 SD. Hydrocortisone treatment was also accompanied by a marked decrease in growth velocity [ Fig. 1(A) ], which illustrates that even physiological amounts of cortisol may have a suppressive effect on growth. Another important clinical observation in our patient was the change in thyroid function. Krude et al.
(2) described similar changes in 2 patients who were already receiving treatment with glucocorticoids and suggested that subclinical hypothyroidism might be a result of POMC-related thyrotropin-releasing hormone deficiency. In our case, the thyroid function almost completely normalized after the start of treatment with hydrocortisone, suggesting that hypothyroidism was glucocorticoid dependent. Subclinical hypothyroidism has been described in patients with other causes of adrenal insufficiency (6); one of the possible mechanisms was the effect of glucocorticoids on the expression of thyrotropin-releasing hormone receptors in the pituitary (7).
Molecular bases of POMC deficiency in our patient were 2 compound heterozygous p.W84X and c.-11C.A mutations. The p.W84X mutation is predicted to result in a marked truncation of POMC preprohormone. The c.-11C.A mutation has been described in several patients of European ancestry and creates an additional out-of-frame translation initiation codon in the 5 0 untranslated region (5 0 UTR) (2). In general, the exact extent of inhibition by a newly appearing uAUG in 5 0 UTR of a particular gene is not easily predictable (8). Aslan et al. press.endocrine.org/journal/jcemposition, is relatively weak for the most efficient uAUG recognition (9) , which enabled us to hypothesize that some degree of the main ORF translation may also be present. Thus, we applied a more sensitive and qualitative approach based on transfection of luciferase mRNA reporters (5, 10). Indeed, using our in vitro system assay, we have demonstrated that the POMC transcript with the maternal mutation was primarily translated from uAUG; however, translation of the main ORF also persisted [up to ;17% of that directed by the wt 5 0 UTR in mammalian cells; Fig. 2(B) ]. The latter implies that c.-11C.A mutation is compatible with secretion of small amounts of POMCderived peptides, which, at least partly, could explain the late presentation of severe hypoglycemia in our patient. Similarly, in the original report by Krude et al. (1) , the patient with the c.-11C.A mutation presented with hypoglycemia at 12 months, which was preceded by severe febrile illness. The patient also showed low-normal level of aMSH, which could additionally point to the partially preserved POMC secretion (1).
Conclusions
The current report provides important information on the natural course of POMC deficiency. In vitro translation studies demonstrated residual translation of the main coding region from an allele with the c.-11C.A mutation, which at least partially explains a relatively late presentation of adrenal insufficiency in the patient.
